首页> Annals of oncology: official journal of the European Society for Medical Oncology> Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

导出原文传递

翻译打印收藏纠错

第一作者： Twelves,C.

作者： Twelves,C. ^[1] ; Scheithauer,W. ^[2] ; Mckendrick,J. ^[3] ; Seitz,J.-F. ^[4] ; VanHazel,G. ^[5] ; Wong,A. ^[6] ; Díaz-Rubio,E. ^[7] ; Gilberg,F. ^[8] ; Cassidy,J. ^[9]

作者单位： F. Hoffmann-La Roche Inc., Basel, Switzerland ^[1] Digestive Oncology Unit, H?pital La Timone, Université de la Méditerranée, Marseille, France ^[2] Department of Medical Oncology, University of Glasgow, Glasgow, United Kingdom ^[3] University of Leeds and St James's Institute of Oncology Hospital, Leeds Cancer Research UK Centre ^[4] Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada ^[5] Department of Internal Medicine I, Medical University Vienna, Vienna, Austria ^[6] Department of Haematology and Medical Oncology, Box Hill Hospital, Melbourne, VIC, Australia ^[7] Perth Oncology, Mount Medical Centre, Perth, WA, Australia ^[8] Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain ^[9]

关键词 5-fluorouracil/folinic acid Adjuvant therapy Capecitabine Colon cancer Elderly Pharmacodynamic markers

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交